Advertisement

 

 

Dabrafenib plus Trametinib Is Active in BRAF(V600E) Anaplastic Thyroid Cancer.

Dabrafenib plus Trametinib Is Active in BRAF(V600E) Anaplastic Thyroid Cancer.
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Cancer discovery 2017 11 10() doi 10.1158/2159-8290.CD-RW2017-212

Abstract

Dual BRAF/MEK inhibition achieves responses in 69% of BRAFV(600E) anaplastic thyroid cancers (ATC).

Submit a Comment

Your email address will not be published. Required fields are marked *

14 − 12 =

[ HIDE/SHOW ]